Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.02 | N/A | +88.57% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.02 | N/A | +88.57% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management focused on the company's long-term vision and ongoing projects. They did not provide specific guidance for the upcoming quarters.
Management highlighted the importance of ongoing research and development efforts.
They emphasized their commitment to innovation in the biotech space.
No specific guidance was provided for future quarters.
This earnings report shows that Moderna managed to beat EPS expectations despite not providing revenue figures. The lack of guidance may leave investors uncertain about the company's future performance. The stock reaction is not available, which makes it difficult to gauge immediate market sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CARNIVAL CORP
Mar 23, 2010